GlaxoSmithKline's new chairman will climb aboard months earlier than expected

GlaxoSmithKline's ($GSK) new chairman will take over several months earlier than expected. When Glaxo tapped Sir Philip Hampton, now chair of Royal Bank of Scotland, to lead its board last fall, his target start date was September of this year. But now, the drugmaker says Hampton is free to take the reins in May. Hampton replaces Christopher Gent, who's been chairman since 2005, at a time when GSK is under pressure from investors to step up its performance. Report

Suggested Articles

Novartis and Civica Rx are patterning up to shore up supply of six key generic injectables used in acute care settings in hospitals.

EU health commissioner Stella Kyriakides reportedly spoke with Gilead execs to iron out a deal to secure remdesivir supply for 16 EU countries.

Under a $1.6 billion deal with the U.S. government, Novavax has pledged to start producing 100 million doses of a COVID-19 vaccine later this year.